Healiva is a patient-centric Biotech commercialising a portfolio of innovative, personalised and affordable life-enhancing precision medicine for chronic and acute wounds. The end-to-end approach has core enzyme technology and is paired with cell therapies or medical devices.

Products, services, technology

Epidex®/Healiva01 is an autologous cell graft promoting the closure of recalcitrant chronic ulcers. Healiva02, an allogeneic cell therapy targets venous leg ulcers. We are further developing 2 in-house products, the world`s first-in class spray based debrider and an autologous blood component patch.

Cooperation possibilities

In-licensing, Out-licensing, Business Development, Distribution.

Open to partner/ collaborate with hospitals, medical practitioners, insurance providers and patients associations.

Some insights
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland